Neurogene, Neoleukin Therapeutics Enter Definitive Merger Agreement To Combine In An All-Stock Transaction
Portfolio Pulse from Benzinga Newsdesk
Neurogene and Neoleukin Therapeutics have entered into a definitive merger agreement. The combined company will operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol 'NGNE'. Neoleukin will issue shares to pre-merger Neurogene stockholders in exchange for the cancellation of shares of Neurogene, making Neurogene a wholly owned subsidiary of Neoleukin.
July 18, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Neoleukin Therapeutics is merging with Neurogene. The combined company will trade under the ticker 'NGNE'. Neoleukin will issue shares to pre-merger Neurogene stockholders.
The merger could potentially lead to a change in the stock price of Neoleukin. However, it is uncertain whether the impact will be positive or negative as it depends on how the market perceives the merger and the future prospects of the combined company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100